Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2406 entries
Sorted by: Best Match Show Resources per page
[Prevalence rate of severely mentally and physically handicapped children in school age in Yokohama].

No to hattatsu = Brain and development

Miyakawa T, Matsui K, Tanaka M, Yamashita S, Miyake S, Yamada M, Iwamoto H, Yokota K.
PMID: 1531017
No To Hattatsu. 1992 Jan;24(1):50-3.

Prevalence rate and pattern of disabilities were studied in severely mentally and physically handicapped children in school age in Yokohama. We visited institutions and schools for retarded children in Yokohama and its neighborhood or made contact with them by...

Cite
Miyakawa T, Matsui K, Tanaka M, et al. [Prevalence rate of severely mentally and physically handicapped children in school age in Yokohama]. No To Hattatsu. 1992;24(1):50-3
Miyakawa, T., Matsui, K., Tanaka, M., Yamashita, S., Miyake, S., Yamada, M., Iwamoto, H., & Yokota, K. (1992). [Prevalence rate of severely mentally and physically handicapped children in school age in Yokohama]. No to hattatsu = Brain and development, 24(1), 50-3.
Miyakawa, T, et al. "[Prevalence rate of severely mentally and physically handicapped children in school age in Yokohama]." No to hattatsu = Brain and development vol. 24,1 (1992): 50-3.
Miyakawa T, Matsui K, Tanaka M, Yamashita S, Miyake S, Yamada M, Iwamoto H, Yokota K. [Prevalence rate of severely mentally and physically handicapped children in school age in Yokohama]. No To Hattatsu. 1992 Jan;24(1):50-3. Japanese. PMID: 1531017.
Copy Download .nbib Format: NLM
[Interviewing technic in health guidance. 2. Analysis of the scene of an interview based on the actual case].

[Hokenfu zasshi] The Japanese journal for public health nurse

Matsuno K, Take K, Osawa K, Sotoma K.
PMID: 5194133
Hokenfu Zasshi. 1969 May;25(5):75-84.

No abstract available.

Cite
Matsuno K, Take K, Osawa K, et al. [Interviewing technic in health guidance. 2. Analysis of the scene of an interview based on the actual case]. Hokenfu Zasshi. 1969;25(5):75-84
Matsuno, K., Take, K., Osawa, K., & Sotoma, K. (1969). [Interviewing technic in health guidance. 2. Analysis of the scene of an interview based on the actual case]. [Hokenfu zasshi] The Japanese journal for public health nurse, 25(5), 75-84.
Matsuno, K, et al. "[Interviewing technic in health guidance. 2. Analysis of the scene of an interview based on the actual case]." [Hokenfu zasshi] The Japanese journal for public health nurse vol. 25,5 (1969): 75-84.
Matsuno K, Take K, Osawa K, Sotoma K. [Interviewing technic in health guidance. 2. Analysis of the scene of an interview based on the actual case]. Hokenfu Zasshi. 1969 May;25(5):75-84. Japanese. PMID: 5194133.
Copy Download .nbib Format: NLM
[Re-evaluation of clinical training in nursing].

[Kango kyoiku] Japanese journal of nurses' education

Matsuo T.
PMID: 3852972
Kango Kyoiku. 1985 Oct;26(10):599-602.

No abstract available.

Cite
Matsuo T. [Re-evaluation of clinical training in nursing]. Kango Kyoiku. 1985;26(10):599-602
Matsuo, T. (1985). [Re-evaluation of clinical training in nursing]. [Kango kyoiku] Japanese journal of nurses' education, 26(10), 599-602.
Matsuo, T. "[Re-evaluation of clinical training in nursing]." [Kango kyoiku] Japanese journal of nurses' education vol. 26,10 (1985): 599-602.
Matsuo T. [Re-evaluation of clinical training in nursing]. Kango Kyoiku. 1985 Oct;26(10):599-602. Japanese. PMID: 3852972.
Copy Download .nbib Format: NLM
[Advances in medical care, ecation and research at the national Hospitals and sanatoria].

Iryo

Matsuo M.
PMID: 5542212
Iryo. 1971 Jan;25(1):1-6.

No abstract available.

Cite
Matsuo M. [Advances in medical care, ecation and research at the national Hospitals and sanatoria]. Iryo. 1971;25(1):1-6
Matsuo, M. (1971). [Advances in medical care, ecation and research at the national Hospitals and sanatoria]. Iryo, 25(1), 1-6.
Matsuo, M. "[Advances in medical care, ecation and research at the national Hospitals and sanatoria]." Iryo vol. 25,1 (1971): 1-6.
Matsuo M. [Advances in medical care, ecation and research at the national Hospitals and sanatoria]. Iryo. 1971 Jan;25(1):1-6. Japanese. PMID: 5542212.
Copy Download .nbib Format: NLM
All-optical switching for 10-Gb/s packet data by using an ultralow-power optical bistability of photonic-crystal nanocavities.

Optics express

Nozaki K, Lacraz A, Shinya A, Matsuo S, Sato T, Takeda K, Kuramochi E, Notomi M.
PMID: 26698517
Opt Express. 2015 Nov 16;23(23):30379-92. doi: 10.1364/OE.23.030379.

An all-optical packet switching using bistable photonic crystal nanocavity memories was demonstrated for the first time. Nanocavity-waveguide coupling systems were configured for 1 × 1, 1 × 2, and 1 × 3 switches for 10-Gb/s optical packet, and they...

Cite
Nozaki K, Lacraz A, Shinya A, et al. All-optical switching for 10-Gb/s packet data by using an ultralow-power optical bistability of photonic-crystal nanocavities. Opt Express. 2015;23(23):30379-92doi: 10.1364/OE.23.030379.
Nozaki, K., Lacraz, A., Shinya, A., Matsuo, S., Sato, T., Takeda, K., Kuramochi, E., & Notomi, M. (2015). All-optical switching for 10-Gb/s packet data by using an ultralow-power optical bistability of photonic-crystal nanocavities. Optics express, 23(23), 30379-92. https://doi.org/10.1364/OE.23.030379
Nozaki, Kengo, et al. "All-optical switching for 10-Gb/s packet data by using an ultralow-power optical bistability of photonic-crystal nanocavities." Optics express vol. 23,23 (2015): 30379-92. doi: https://doi.org/10.1364/OE.23.030379
Nozaki K, Lacraz A, Shinya A, Matsuo S, Sato T, Takeda K, Kuramochi E, Notomi M. All-optical switching for 10-Gb/s packet data by using an ultralow-power optical bistability of photonic-crystal nanocavities. Opt Express. 2015 Nov 16;23(23):30379-92. doi: 10.1364/OE.23.030379. PMID: 26698517.
Copy Download .nbib Format: NLM
Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Tanaka H, Yamaguchi T, Hachiya K, Hayashi M, Ogawa S, Nishibori H, Kamei S, Ishihara S, Matsuo M, Kellam SG.
PMID: 28951699
Rep Pract Oncol Radiother. 2017 Nov-Dec;22(6):477-481. doi: 10.1016/j.rpor.2017.08.009. Epub 2017 Sep 19.

AIM: To assess the changes in prostate size in patients with prostate cancer undergoing intensity-modulated radiation therapy (IMRT).BACKGROUND: The effect of size change produced by IMRT is not well known.MATERIALS AND METHODS: We enrolled 72 patients who received IMRT...

Cite
Tanaka H, Yamaguchi T, Hachiya K, et al. Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone. Rep Pract Oncol Radiother. 2017;22(6):477-481doi: 10.1016/j.rpor.2017.08.009.
Tanaka, H., Yamaguchi, T., Hachiya, K., Hayashi, M., Ogawa, S., Nishibori, H., Kamei, S., Ishihara, S., Matsuo, M., & Kellam, S. G. (2017). Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 22(6), 477-481. https://doi.org/10.1016/j.rpor.2017.08.009
Tanaka, Hidekazu, et al. "Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone." Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology vol. 22,6 (2017): 477-481. doi: https://doi.org/10.1016/j.rpor.2017.08.009
Tanaka H, Yamaguchi T, Hachiya K, Hayashi M, Ogawa S, Nishibori H, Kamei S, Ishihara S, Matsuo M, Kellam SG. Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone. Rep Pract Oncol Radiother. 2017 Nov-Dec;22(6):477-481. doi: 10.1016/j.rpor.2017.08.009. Epub 2017 Sep 19. PMID: 28951699; PMCID: PMC5607145.
Copy Download .nbib Format: NLM
Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.

Oncotarget

Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T.
PMID: 28977890
Oncotarget. 2017 Jun 27;8(37):61618-61625. doi: 10.18632/oncotarget.18651. eCollection 2017 Sep 22.

Programmed cell death 1 (PD-1) receptor-ligand interaction is a major pathway that is often hijacked by tumors to suppress immune control. Immunoscore (IS), a combinational index of CD3 and CD8 tumor-infiltrating lymphocyte (TIL) density in the tumor's center and...

Cite
Ishii H, Azuma K, Kawahara A, et al. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget. 2017;8(37):61618-61625doi: 10.18632/oncotarget.18651.
Ishii, H., Azuma, K., Kawahara, A., Matsuo, N., Tokito, T., Kinoshita, T., Yamada, K., Sasada, T., Akiba, J., & Hoshino, T. (2017). Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget, 8(37), 61618-61625. https://doi.org/10.18632/oncotarget.18651
Ishii, Hidenobu, et al. "Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy." Oncotarget vol. 8,37 (2017): 61618-61625. doi: https://doi.org/10.18632/oncotarget.18651
Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget. 2017 Jun 27;8(37):61618-61625. doi: 10.18632/oncotarget.18651. eCollection 2017 Sep 22. PMID: 28977890; PMCID: PMC5617450.
Copy Download .nbib Format: NLM
Edge mixing dynamics in graphene p-n junctions in the quantum Hall regime.

Nature communications

Matsuo S, Takeshita S, Tanaka T, Nakaharai S, Tsukagoshi K, Moriyama T, Ono T, Kobayashi K.
PMID: 26337445
Nat Commun. 2015 Sep 04;6:8066. doi: 10.1038/ncomms9066.

Massless Dirac electron systems such as graphene exhibit a distinct half-integer quantum Hall effect, and in the bipolar transport regime co-propagating edge states along the p-n junction are realized. Additionally, these edge states are uniformly mixed at the junction,...

Cite
Matsuo S, Takeshita S, Tanaka T, et al. Edge mixing dynamics in graphene p-n junctions in the quantum Hall regime. Nat Commun. 2015;6:8066doi: 10.1038/ncomms9066.
Matsuo, S., Takeshita, S., Tanaka, T., Nakaharai, S., Tsukagoshi, K., Moriyama, T., Ono, T., & Kobayashi, K. (2015). Edge mixing dynamics in graphene p-n junctions in the quantum Hall regime. Nature communications, 68066. https://doi.org/10.1038/ncomms9066
Matsuo, Sadashige, et al. "Edge mixing dynamics in graphene p-n junctions in the quantum Hall regime." Nature communications vol. 6 (2015): 8066. doi: https://doi.org/10.1038/ncomms9066
Matsuo S, Takeshita S, Tanaka T, Nakaharai S, Tsukagoshi K, Moriyama T, Ono T, Kobayashi K. Edge mixing dynamics in graphene p-n junctions in the quantum Hall regime. Nat Commun. 2015 Sep 04;6:8066. doi: 10.1038/ncomms9066. PMID: 26337445; PMCID: PMC4569692.
Copy Download .nbib Format: NLM
How far is observation allowed in patients with ectopia lentis?.

SpringerPlus

Matsuo T.
PMID: 26339562
Springerplus. 2015 Aug 28;4:461. doi: 10.1186/s40064-015-1239-5. eCollection 2015.

Surgical timing for ectopia lentis has not been well described until now. The purpose of this study is to find a benchmark as to how far observation would be allowed in children with ectopia lentis when they and their...

Cite
Matsuo T. How far is observation allowed in patients with ectopia lentis?. Springerplus. 2015;4:461doi: 10.1186/s40064-015-1239-5.
Matsuo, T. (2015). How far is observation allowed in patients with ectopia lentis?. SpringerPlus, 4461. https://doi.org/10.1186/s40064-015-1239-5
Matsuo, Toshihiko. "How far is observation allowed in patients with ectopia lentis?." SpringerPlus vol. 4 (2015): 461. doi: https://doi.org/10.1186/s40064-015-1239-5
Matsuo T. How far is observation allowed in patients with ectopia lentis?. Springerplus. 2015 Aug 28;4:461. doi: 10.1186/s40064-015-1239-5. eCollection 2015. PMID: 26339562; PMCID: PMC4551678.
Copy Download .nbib Format: NLM
Alteration of swing leg work and power during human accelerated sprinting.

Biology open

Nagahara R, Matsubayashi T, Matsuo A, Zushi K.
PMID: 28396485
Biol Open. 2017 May 15;6(5):633-641. doi: 10.1242/bio.024281.

This study investigated changes in lower-extremity joint work and power during the swing phase in a maximal accelerated sprinting. Twelve male sprinters performed 60 m maximal sprints while motion data was recorded. Lower-extremity joint work and power during the...

Cite
Nagahara R, Matsubayashi T, Matsuo A, et al. Alteration of swing leg work and power during human accelerated sprinting. Biol Open. 2017;6(5):633-641doi: 10.1242/bio.024281.
Nagahara, R., Matsubayashi, T., Matsuo, A., & Zushi, K. (2017). Alteration of swing leg work and power during human accelerated sprinting. Biology open, 6(5), 633-641. https://doi.org/10.1242/bio.024281
Nagahara, Ryu, et al. "Alteration of swing leg work and power during human accelerated sprinting." Biology open vol. 6,5 (2017): 633-641. doi: https://doi.org/10.1242/bio.024281
Nagahara R, Matsubayashi T, Matsuo A, Zushi K. Alteration of swing leg work and power during human accelerated sprinting. Biol Open. 2017 May 15;6(5):633-641. doi: 10.1242/bio.024281. PMID: 28396485; PMCID: PMC5450322.
Copy Download .nbib Format: NLM
Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Oncology letters

Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H.
PMID: 28356963
Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

In patients with advanced urothelial cancer (UC), a combination of cisplatin (CDDP) and gemcitabine (GEM) is the most commonly used first-line systematic chemotherapy regimen. Although no standard regime for the treatment of CDDP-resistant UC has been established, GEM-based regimens...

Cite
Miyata Y, Mitsunari K, Akihiro A, et al. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett. 2016;13(2):811-818doi: 10.3892/ol.2016.5484.
Miyata, Y., Mitsunari, K., Akihiro, A., Watanabe, S. I., Matsuo, T., Ohba, K., & Sakai, H. (2017). Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncology letters, 13(2), 811-818. https://doi.org/10.3892/ol.2016.5484
Miyata, Yasuyoshi, et al. "Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer." Oncology letters vol. 13,2 (2017): 811-818. doi: https://doi.org/10.3892/ol.2016.5484
Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12. PMID: 28356963; PMCID: PMC5351343.
Copy Download .nbib Format: NLM
Prognostic significance of KLF4 expression in gastric cancer.

Oncology letters

Hashimoto I, Nagata T, Sekine S, Moriyama M, Shibuya K, Hojo S, Matsui K, Yoshioka I, Okumura T, Hori T, Shimada Y, Tsukada K.
PMID: 28356964
Oncol Lett. 2017 Feb;13(2):819-826. doi: 10.3892/ol.2016.5499. Epub 2016 Dec 14.

To understand the roles of pluripotent stem cell-inducing genes in gastric cancer, the expression of Krüppel-like factor 4 (KLF4), Nanog, octamer-binding transcription factor 4 (Oct4), avian myelocytomatosis viral oncogene homolog (c-Myc) and sex-determining region Y-box 2 (SOX2) was examined...

Cite
Hashimoto I, Nagata T, Sekine S, et al. Prognostic significance of KLF4 expression in gastric cancer. Oncol Lett. 2016;13(2):819-826doi: 10.3892/ol.2016.5499.
Hashimoto, I., Nagata, T., Sekine, S., Moriyama, M., Shibuya, K., Hojo, S., Matsui, K., Yoshioka, I., Okumura, T., Hori, T., Shimada, Y., & Tsukada, K. (2017). Prognostic significance of KLF4 expression in gastric cancer. Oncology letters, 13(2), 819-826. https://doi.org/10.3892/ol.2016.5499
Hashimoto, Isaya, et al. "Prognostic significance of KLF4 expression in gastric cancer." Oncology letters vol. 13,2 (2017): 819-826. doi: https://doi.org/10.3892/ol.2016.5499
Hashimoto I, Nagata T, Sekine S, Moriyama M, Shibuya K, Hojo S, Matsui K, Yoshioka I, Okumura T, Hori T, Shimada Y, Tsukada K. Prognostic significance of KLF4 expression in gastric cancer. Oncol Lett. 2017 Feb;13(2):819-826. doi: 10.3892/ol.2016.5499. Epub 2016 Dec 14. PMID: 28356964; PMCID: PMC5351303.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2406 entries